352 related articles for article (PubMed ID: 12044509)
1. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup.
Hauben EI; Weeden S; Pringle J; Van Marck EA; Hogendoorn PC
Eur J Cancer; 2002 Jun; 38(9):1218-25. PubMed ID: 12044509
[TBL] [Abstract][Full Text] [Related]
2. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.
Smeland S; Bielack SS; Whelan J; Bernstein M; Hogendoorn P; Krailo MD; Gorlick R; Janeway KA; Ingleby FC; Anninga J; Antal I; Arndt C; Brown KLB; Butterfass-Bahloul T; Calaminus G; Capra M; Dhooge C; Eriksson M; Flanagan AM; Friedel G; Gebhardt MC; Gelderblom H; Goldsby R; Grier HE; Grimer R; Hawkins DS; Hecker-Nolting S; Sundby Hall K; Isakoff MS; Jovic G; Kühne T; Kager L; von Kalle T; Kabickova E; Lang S; Lau CC; Leavey PJ; Lessnick SL; Mascarenhas L; Mayer-Steinacker R; Meyers PA; Nagarajan R; Randall RL; Reichardt P; Renard M; Rechnitzer C; Schwartz CL; Strauss S; Teot L; Timmermann B; Sydes MR; Marina N
Eur J Cancer; 2019 Mar; 109():36-50. PubMed ID: 30685685
[TBL] [Abstract][Full Text] [Related]
3. Local host response in osteosarcoma after chemotherapy referred to radiographs, CT, tumour necrosis and patient survival.
Lindner NJ; Scarborough MT; Spanier SS; Enneking WF
J Cancer Res Clin Oncol; 1998; 124(10):575-80. PubMed ID: 9829862
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.
Bacci G; Ferrari S; Delepine N; Bertoni F; Picci P; Mercuri M; Bacchini P; Brach del Prever A; Tienghi A; Comandone A; Campanacci M
J Clin Oncol; 1998 Feb; 16(2):658-63. PubMed ID: 9469355
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
6. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup.
McTiernan A; Jinks RC; Sydes MR; Uscinska B; Hook JM; van Glabbeke M; Bramwell V; Lewis IJ; Taminiau AH; Nooij MA; Hogendoorn PC; Gelderblom H; Whelan JS
Eur J Cancer; 2012 Mar; 48(5):703-12. PubMed ID: 22036088
[TBL] [Abstract][Full Text] [Related]
7. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
Tsuda Y; Tsoi K; Parry MC; Stevenson JD; Fujiwara T; Sumathi V; Jeys LM
Bone Joint J; 2020 Jun; 102-B(6):795-803. PubMed ID: 32475245
[TBL] [Abstract][Full Text] [Related]
8. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup.
Souhami RL; Craft AW; Van der Eijken JW; Nooij M; Spooner D; Bramwell VH; Wierzbicki R; Malcolm AJ; Kirkpatrick A; Uscinska BM; Van Glabbeke M; Machin D
Lancet; 1997 Sep; 350(9082):911-7. PubMed ID: 9314869
[TBL] [Abstract][Full Text] [Related]
9. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders.
Smeland S; Müller C; Alvegard TA; Wiklund T; Wiebe T; Björk O; Stenwig AE; Willén H; Holmström T; Follerås G; Brosjö O; Kivioja A; Jonsson K; Monge O; Saeter G
Eur J Cancer; 2003 Mar; 39(4):488-94. PubMed ID: 12751380
[TBL] [Abstract][Full Text] [Related]
10. Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy,
Bacci G; Ferrari S; Bertoni F; Picci P; Bacchini P; Longhi A; Donati D; Forni C; Campanacci L; Campanacci M
Clin Orthop Relat Res; 2001 May; (386):186-96. PubMed ID: 11347833
[TBL] [Abstract][Full Text] [Related]
11. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.
Lewis IJ; Nooij MA; Whelan J; Sydes MR; Grimer R; Hogendoorn PC; Memon MA; Weeden S; Uscinska BM; van Glabbeke M; Kirkpatrick A; Hauben EI; Craft AW; Taminiau AH; ;
J Natl Cancer Inst; 2007 Jan; 99(2):112-28. PubMed ID: 17227995
[TBL] [Abstract][Full Text] [Related]
12. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.
Bacci G; Picci P; Ferrari S; Ruggieri P; Casadei R; Tienghi A; Brach del Prever A; Gherlinzoni F; Mercuri M; Monti C
Cancer; 1993 Dec; 72(11):3227-38. PubMed ID: 8242546
[TBL] [Abstract][Full Text] [Related]
13. Correlation between apparent diffusion coefficient and histopathology subtypes of osteosarcoma after neoadjuvant chemotherapy.
Wang J; Sun M; Liu D; Hu X; Pui MH; Meng Q; Gao Z
Acta Radiol; 2017 Aug; 58(8):971-976. PubMed ID: 27852643
[TBL] [Abstract][Full Text] [Related]
14. Osteosarcoma of the pelvis: a monoinstitutional experience in patients younger than 41 years.
Ferrari S; Palmerini E; Fabbri N; Staals E; Ferrari C; Alberghini M; Picci P
Tumori; 2012 Nov; 98(6):702-8. PubMed ID: 23389355
[TBL] [Abstract][Full Text] [Related]
15. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup.
Bramwell VH; Burgers M; Sneath R; Souhami R; van Oosterom AT; Voûte PA; Rouesse J; Spooner D; Craft AW; Somers R
J Clin Oncol; 1992 Oct; 10(10):1579-91. PubMed ID: 1403038
[TBL] [Abstract][Full Text] [Related]
16. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials.
Whelan JS; Jinks RC; McTiernan A; Sydes MR; Hook JM; Trani L; Uscinska B; Bramwell V; Lewis IJ; Nooij MA; van Glabbeke M; Grimer RJ; Hogendoorn PC; Taminiau AH; Gelderblom H
Ann Oncol; 2012 Jun; 23(6):1607-16. PubMed ID: 22015453
[TBL] [Abstract][Full Text] [Related]
17. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of short-course intensive multiagent chemotherapy in metastatic and axial skeletal osteosarcoma.
Janinis J; McTiernan A; Driver D; Mitchell C; Cassoni AM; Pringle J; Kilby A; Whelan JS;
Ann Oncol; 2002 Dec; 13(12):1935-44. PubMed ID: 12453863
[TBL] [Abstract][Full Text] [Related]
19. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials.
Gelderblom H; Jinks RC; Sydes M; Bramwell VH; van Glabbeke M; Grimer RJ; Hogendoorn PC; McTiernan A; Lewis IJ; Nooij MA; Taminiau AH; Whelan J;
Eur J Cancer; 2011 Apr; 47(6):895-902. PubMed ID: 21216138
[TBL] [Abstract][Full Text] [Related]
20. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
